Riester Daniel, Wirsching Frank, Salinas Gabriela, Keller Martina, Gebinoga Michael, Kamphausen Stefan, Merkwirth Christian, Goetz Ruediger, Wiesenfeldt Martin, Stürzebecher Jörg, Bode Wolfram, Friedrich Rainer, Thürk Marcel, Schwienhorst Andreas
Abteilung für Molekulare Genetik und Präparative Molekularbiologie, Institut für Mikrobiologie und Genetik, Grisebachstrasse 8, 37077 Göttingen, Germany.
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8597-602. doi: 10.1073/pnas.0501983102. Epub 2005 Jun 3.
Here, we present a series of thrombin inhibitors that were generated by using powerful computer-assisted multiparameter optimization process. The process was organized in design cycles, starting with a set of randomly chosen molecules. Each cycle combined combinatorial synthesis, multiparameter characterization of compounds in a variety of bioassays, and algorithmic processing of the data to devise a set of compounds to be synthesized in the next cycle. The identified lead compounds exhibited thrombin inhibitory constants in the lower nanomolar range. They are by far the most selective synthetic thrombin inhibitors, with selectivities of >100,000-fold toward other proteases such as Factor Xa, Factor XIIa, urokinase, plasmin, and Plasma kallikrein. Furthermore, these compounds exhibit a favorable profile, comprising nontoxicity, high metabolic stability, low serum protein binding, good solubility, high anticoagulant activity, and a slow and exclusively renal elimination from the circulation in a rat model. Finally, x-ray crystallographic analysis of a thrombin-inhibitor complex revealed a binding mode with a neutral moiety in the S1 pocket of thrombin.
在此,我们展示了一系列通过强大的计算机辅助多参数优化过程生成的凝血酶抑制剂。该过程按设计周期组织,从一组随机选择的分子开始。每个周期都结合了组合合成、在多种生物测定中对化合物的多参数表征以及对数据的算法处理,以设计出在下一个周期中要合成的一组化合物。所鉴定的先导化合物在较低的纳摩尔范围内表现出凝血酶抑制常数。它们是迄今为止最具选择性的合成凝血酶抑制剂,对其他蛋白酶如因子Xa、因子XIIa、尿激酶、纤溶酶和血浆激肽释放酶的选择性大于100,000倍。此外,这些化合物具有良好的特性,包括无毒性、高代谢稳定性、低血清蛋白结合率、良好的溶解性、高抗凝活性以及在大鼠模型中从循环中缓慢且仅通过肾脏消除。最后,凝血酶 - 抑制剂复合物的X射线晶体学分析揭示了在凝血酶S1口袋中与中性部分的结合模式。